Current approaches and future strategies for pancreatic carcinoma.
作者： Robert A. Wolff , Paul Chiao , Renato Lenzi , Peter W.T. Pisters , Jeffrey E. Lee
关键词: Pancreatic disease 、 Epidermal growth factor receptor 、 Immunology 、 Internal medicine 、 Pancreatic cancer 、 Clinical trial 、 Gemcitabine 、 Oncology 、 Pancreas 、 Radiation therapy 、 Metastasis 、 Medicine
摘要: Pancreatic cancer is a lethal disease characterized by local invasion and early dissemination. It resistant to conventional surgical, radiotherapeutic, chemotherapeutic modalities. These interventions have had minimal impact on overall survival with very few patients enjoying long term survival. Over the past years, 2'difluoro-2'deoxycytidine (gemcitabine) has demonstrated modest activity in this investigations are proceeding expand its role combination radiotherapy other agents. In addition, identification of molecular defects underlying suggested targets for design rational systemic therapy. include matrix metalloproteinases, K-ras, HER2/neu, p53, epidermal growth factor receptor. Current future clinical trials designed improve pancreatic will be discussed.
springer.com
sci-hub.se 参考文章(92)
L.J. Denis, J. Verweij, Matrix metalloproteinase inhibitors: Present achievements and future prospects Investigational New Drugs. ,vol. 15, pp. 175- 185 ,(1997) , 10.1023/A:1005855905442
Rolf J. Weinel, Kurt Neumann, Oliver Kisker, Annette Rosendahl, Expression and potential role of E-cadherin in pancreatic carcinoma. International Journal of Pancreatology. ,vol. 19, pp. 25- 30 ,(1996) , 10.1007/BF02788372
Buchler M, Korc M, Kobrin Ms, Yamanaka Y, Friess H, Beger Hg, Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Research. ,vol. 13, pp. 565- 569 ,(1993)
N S Pellegata, B Renault, F Sessa, E Solcia, G N Ranzani, M Bonato, B E Leone, K-ras and p53 Gene Mutations in Pancreatic Cancer: Ductal and Nonductal Tumors Progress through Different Genetic Lesions Cancer Research. ,vol. 54, pp. 1556- 1560 ,(1994)
R. H. Hruban, T. W. Kensler, D. H.J. Van Weering, J. L. Cameron, S. N. Goodman, A. D.M. Van Mansfeld, K. K. Bose, David C. Allison, G. J.A. Offerhaus, J. L. Bos, K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. American Journal of Pathology. ,vol. 143, pp. 545- 554 ,(1993)
Richard M. Lush, M. Wayne Saville, Robert Yarchoan, Eddie Reed, William D. Figg, Kathy Wyvill, James M. Pluda, The Pharmacokinetics of TNP‐470, a New Angiogenesis Inhibitor Pharmacotherapy. ,vol. 17, pp. 91- 97 ,(1997) , 10.1002/J.1875-9114.1997.TB03680.X
Antonio L. Cubilla, Patrick J. Fitzgerald, Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Research. ,vol. 36, pp. 2690- 2698 ,(1976)
Frank V Fossella, Scott M Lippman, Dong M Shin, Peter Tarassoff, Maria Calayag-Jung, Roman Perez-Soler, Jin Soo Lee, William K Murphy, Bonnie Glisson, Edgardo Rivera, Waun Ki Hong, None, Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 15, pp. 310- 316 ,(1997) , 10.1200/JCO.1997.15.1.310
J L Abbruzzese, R Grunewald, E A Weeks, D Gravel, T Adams, B Nowak, S Mineishi, P Tarassoff, W Satterlee, M N Raber, A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. Journal of Clinical Oncology. ,vol. 9, pp. 491- 498 ,(1991) , 10.1200/JCO.1991.9.3.491
Françoise Guéritte-Voegelein, François Lavelle, Daniel Guénard, Marie-Christine Bissery, Experimental Antitumor Activity of Taxotere (RP 56976, NSC 628503), a Taxol Analogue Cancer Research. ,vol. 51, pp. 4845- 4852 ,(1991)